Trega Biosciences (TRGA), formerly HPIP Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sam who wrote (25)	10/6/1997 12:22:00 AM
From: bob zagorin	of 152

Michael Murphy (CTSL) confirms TRGA will host analyst meeting this week the day before presenting at Cal Bio conference. He makes TRGA his #2 biotech pick this week on hotline (FWIW). here also is quote from PR announcing the conf. and featured address by TRGA CEO. Company executives will present leading technological aspects with the "New Discovery Tool Box" segment. Presentations include "High-Throughput Screening" by Gordon Foulkes, of Aurora Biosciences; "Target Identification" by Kevin Kinsella, chief executive officer of Sequana Therapeutics ; and "Combinatorial Chemistry" by Robert Whitehead, chairman of CalBioSummit '97 and CEO of Trega Biosciences. "Today it takes about $200 million to $300 million and seven years to get a new drug to the market" said Whitehead. "Approximately 45-50 percent of this money and 40 percent of the time are consumed identifying appropriate new drug candidates. Typically, 10,000 potential drug candidates need to be screened to identify a single compound that can be advanced to pre-clinical testing."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next